Pacylex Pharmaceuticals Reports Safety and Efficacy Results from Its Phase 1 First-In-Human Study of Zelenirstat (PCLX-001) Pacylex’s CEO Will Present at Two Upcoming Life Science Investment Conferences

Pacylex recently reported results at the Canadian Association of Radiation Oncology highlighting that zelenirstat was more effective than clinically used radiosensitizers

A myristoylation inhibition gene expression signature, MISS-91 (Myristoylation Inhibitors Sensitivity Signature), will be presented at the European Association for Cancer Research (EACR) 2023 Congress.

The first patient has been dosed with PCLX-001 monotherapy, a first-in-class, oral small molecule N-myristoyltransferase (NMT) inhibitor, in a Phase 2a expansion study. The expansion study will enroll up to 20 patients.

A myristoylation inhibition gene expression signature, MISS-91 (Myristoylation Inhibition Sensitivity Signature), will be unveiled at the American Association for Cancer Research (AACR) Annual Meeting.

Pacylex was selected by a panel of pharmaceutical industry professionals to be one of 16 Canadian companies to present at the 3rd annual Sweet Biopharma Day, an invitation-only event, on April 12, 2023.

We are happy to bring on Michele Libonati to the role of Chief Operating Officer (COO) and Annette Marcantonio to the role of Vice President of Clinical Operations

Pacylex to present an update on clinical progress of PCLX-001 and Series B plans for Pacylex Pharmaceuticals at Biotech Showcase™ 2023. Presentation held on Tuesday, January 10, 2023 at 10:45am PT in the Franciscan A Room.

Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia First in class therapy moves closer to clinical trial of PCLX-001 in Acute Myeloid Leukemia